title: An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?
abstract: BACKGROUND
  Glycopeptides are often used for persistent fever in neutropenic patients. This study compares efficacy and toxicity of teicoplanin and vancomycin.
  
  
  METHODS
  Hundred consecutive neutropenic patients with hematological malignancies and persistent fever after 72 h of first-line antibiotic therapy (91% piperacillin/tazobactam) were treated with teicoplanin (800 mg on day 1, then 400 mg/day)+piperacillin/tazobactam+gentamicin from 08/96 to 09/00 (group T) or with vancomycin (2 g/day)+meropenem+levofloxacin from 10/00 to 04/02 (group V). Success was defervescence (>or=7 days) in absence of any sign of continuing infection. Nephrotoxicity was monitored daily as increase in serum creatinine.
  
  
  RESULTS
  Fifty patients were analyzed in each group. Efficacy was evaluated in patients with piperacillin/tazobactam as first-line therapy only. Treatment was successful in 76% in group T (n=42) and 59% in group V (n=49), p=0.118. Toxicity was evaluated in all patients. The median increase of creatinine was 11% (interquartile range 0%-30%) in group T and 17% (0%-74%) in group V, p=0.062. In patients who received concomitant amphotericin B (given for 7 days and 6 days, respectively, p=0.525), median creatinine increased from 0.9 mg/dl (0.8-1.1) to 1.2 mg/dl (0.9-1.5) in group T and from 0.9 mg/dl (0.8-1.08) to 1.55 mg/dl (1.33-2.23) in group V (p<0.001). This led to a doubling of creatinine in 2/23 (9%) patients of group T and in 9/16 (56%) patients of group V (p=0.003). A multivariate analysis revealed that concomitant use of amphotericin B (p<0.001) and treatment with vancomycin (p=0.002) were independently associated with nephrotoxicity.
  
  
  CONCLUSIONS
  Teicoplanin and vancomycin were comparably effective in patients with neutropenia and persistent fever, but - if combined with amphotericin B - vancomycin was significantly more nephrotoxic than teicoplanin.
authors.affiliation: Department of Internal Medicine I, University of Bonn, Bonn, Germany, corinna.hahn@uni-bonn.de
authors.forename: C
authors.initials: C
authors.lastname: Hahn-Ast
authors.forename: A
authors.initials: A
authors.lastname: Glasmacher
authors.forename: A
authors.initials: A
authors.lastname: Arns
authors.forename: A
authors.initials: A
authors.lastname: Mühling
authors.forename: K
authors.initials: K
authors.lastname: Orlopp
authors.forename: G
authors.initials: G
authors.lastname: Marklein
authors.forename: M
authors.initials: M
authors.lastname: Von Lilienfeld-Toal
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003401:Creatine / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D005334:Fever / Q000209:etiology; D005335:Fever of Unknown Origin / Q000209:etiology; D006801:Humans; D007239:Infections / Q000188:drug therapy* / Q000209:etiology; D007668:Kidney / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009503:Neutropenia / Q000209:etiology*; D017334:Teicoplanin / Q000009:adverse effects / Q000627:therapeutic use*; D014640:Vancomycin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D017334:Teicoplanin; D014640:Vancomycin; D003401:Creatine